Monogram Biosciences' PhenoSense RH/IN assay is a novel phenotypic assay that measures the susceptibility of inhibitors of HIV-1 integrase (IN) and RNaseH (RH), as well as the replication capacity of patient viruses with reduced susceptibility to such inhibitors. With promising integrase inhibitors (INIs) in development, there is considerable need for a phenotypic assay, for monitoring drug susceptibility in patients, as well as assisting in antiviral drug discovery and development. Monogram's PhenoSense HIV assay has been adapted to measure inhibition of recombinant viruses containing patient-derived integrase coding sequences by INIs. With these modifications, INIs can be assayed in the same manner as reverse transcriptase inhibitors (RTIs). The GeneSeq HIV Integrase assay provides complementary sequence data of integrase and RNaseH. Both of Monogram's Integrase assays are actively used in ongoing clinical studies of new integrase inhibitors.

Click here to download the poster: Fransen, S., Gupta, S., Paxinos, E. E., Huang, W., Parkin, N., Miller, M., Hazuda, D., Petropoulos, C. J.
Integrase (IN) Inhibitor Susceptibility Can Be Measured Using Recombinant Viruses That Express Patient Virus IN Alone, or in Combination with Protease (PR) and Reverse Transcriptase (RT). S. Fransen et al; 12th Conference on Retroviruses and Opportunistic Infections, February 2005, Boston

For more information on Monogram assays, services and pricing, please contact us.